The Procter Gamble Company

Jeffrey Joseph Ares

Thomas L Cupps

Russell James Sheldon

Raymond Todd Henry

William Lee Seibel

Sophie Eva Bogdan

Peter J Maurer

Daniel P Walker

Gary Robert Kelm

Jared Lynn Randall

Sunil V Kakodkar

Candice L Slough

Peter D Murray

Glen E Mieling

Guanidinylamino heterocycle compounds useful as &agr;-2 adrenoceptor agonists

Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists

This invention involves compounds having the following structure

Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists

This invention involves compounds having the following structure:

This invention involves compounds having the structure (I) as described in the claims, and enantiomers,optical isomers, stereoisomers, diastereomers, tautomers, addition salts, biohydrolyzable amides and esters thereof, as well as pharmaceutical compositions comprising such noved compounds. The invention also relates to the use of such compounds for preventing or treating disorders modulated by alpha-2 adrenoceptors.

The subject invention relates to compounds having the structure: ##STR1## wherein (a) n is an integer from 1 to about 3;

2-Imidazolinylamino heterocyclic compounds useful as alpha-2

2-imidazolinylamino heterocyclic compounds useful as alpha-2

The subject invention relates to compounds having the structure: ##STR1## as defined in the claims, and to pharmaceutical compositions containing such compounds, and the use of such compounds for preventing or treating of disorders modulated by alpha-2 adrenoceptors.

6-(2-imidazolinylamino) quinolines useful as alpha-2 adrenoceptor

The subject invention relates to compounds having the structure: ##STR1## wherein: (a) R is unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl;

6-(2-Imidazolinylamino) quinoline compounds useful as alpha-2

6-(2-imidazolinylamino)quinoline compounds useful as alpha-2

The subject invention relates to methods for preventing or treating damage to the mucosal lining of the gastrointestinal tract of a human or lower animal by administering a safe and effective amount of a compound having the structure: ##STR1## wherein X and Y are each independently selected from O and S; R.sup.1, R.sup.2 and R.sup.3 are each independently selected from hydrogen, hydroxy, halo, unsubstituted or monosubstituted straight or branched C.sub.1 -C.sub.4 alkanyl, and unsubstituted or substituted straight or branched C.sub.1 -C.sub.4 alkanoxy; and each of R.sup.4, R.sup.5, R.sup.6 and R.sup.7 is hydrogen or, if one or more of R.sup.1, R.sup.2 and R.sup.3 is other than hydrogen, each of R.sup.4, R.sup.5, R.sup.6 and R.sup.7 is selected from hydrogen, halo, trifluoromethyl, and unsubstituted straight or branched C.sub.1 -C.sub.4 alkanyl.

Growing community of inventors

Hamilton, OH, United States of America

Jeffrey Joseph Ares